Display options
Cite
Zhang M, Tan X, Huang J, et al. Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis. Onco Targets Ther. 2016;9:2181-92doi: 10.2147/OTT.S94761.
Zhang, M., Tan, X., Huang, J., Xie, L., Wang, H., Shi, J., Lu, W., Lv, Z., Mei, H., & Liang, C. (2016). Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis. OncoTargets and therapy, 92181-92. https://doi.org/10.2147/OTT.S94761
Zhang, Meng, et al. "Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis." OncoTargets and therapy vol. 9 (2016): 2181-92. doi: https://doi.org/10.2147/OTT.S94761
Zhang M, Tan X, Huang J, Xie L, Wang H, Shi J, Lu W, Lv Z, Mei H, Liang C. Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis. Onco Targets Ther. 2016 Apr 19;9:2181-92. doi: 10.2147/OTT.S94761. eCollection 2016. PMID: 27143914; PMCID: PMC4846049.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2016 Apr 19;9:2181-92. doi: 10.2147/OTT.S94761. eCollection 2016.

Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis.

OncoTargets and therapy

Meng Zhang, Xiuxiu Tan, Junjie Huang, Lijuan Xie, Hao Wang, Jizhou Shi, Wei Lu, Zhaojie Lv, Hongbing Mei, Chaozhao Liang

Affiliations

  1. Department of Urology, Shenzhen Second People's Hospital, Clinical Medicine of Anhui Medical University, Hefei, Peoples Republic of China; Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, Peoples Republic of China.
  2. Department of Urology, Shenzhen Second People's Hospital, Clinical Medicine of Anhui Medical University, Hefei, Peoples Republic of China.
  3. Department of Hematology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Peoples Republic of China.
  4. Department of Urology, Shengli Oilfield Central Hospital, Dongying, Peoples Republic of China.
  5. Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, Peoples Republic of China.

PMID: 27143914 PMCID: PMC4846049 DOI: 10.2147/OTT.S94761

Abstract

BACKGROUND: Several epidemiological studies have illustrated that polymorphisms in interleukin-2 (IL-2) were associated with diverse cancer types. However, recently published statistics were inconsistent and inconclusive. Therefore, the current meta-analysis was performed to elaborate the effects of IL-2 polymorphisms (rs2069762 and rs2069763) on cancer susceptibility.

MATERIAL AND METHODS: A total of 5,601 cancer cases and 7,809 controls from 21 published case-control studies were enrolled in our meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between IL-2 polymorphisms and cancer susceptibility.

RESULTS: Our study demonstrated an increased susceptibility to cancer in rs2069762 (G vs T: OR =1.268, 95% CI =1.113-1.445; GG vs TT: OR =1.801, 95% CI =1.289-2.516; GT vs TT: OR =1.250, 95% CI =1.061-1.473; GG + GT vs TT: OR =1.329, 95% CI =1.118-1.579; GG vs GT + TT: OR =1.536, 95% CI =1.162-2.030). In the subgroup analysis, increased susceptibility to cancer was identified in the hospital-based group and P HWE<0.05 (P-value of the Hardy-Weinberg equilibrium [HWE]) group. In addition, a positive association with cancer susceptibility was observed among both Chinese and non-Chinese. However, no relationship was detected between the rs2069763 polymorphism of IL-2 and cancer susceptibility.

CONCLUSION: To conclude, rs2069762 polymorphism of IL-2 contributed to an increased susceptibility to cancer, whereas no association was identified between rs2069763 polymorphism and cancer susceptibility. Further detailed studies are warranted to confirm our findings.

Keywords: IL-2; cancer; meta-analysis; polymorphism

References

  1. J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1195-202 - PubMed
  2. J Mol Med (Berl). 2010 Apr;88(4):423-9 - PubMed
  3. Braz J Med Biol Res. 2011 Oct;44(10):1006-12 - PubMed
  4. Nat Rev Drug Discov. 2012 Oct;11(10):790-811 - PubMed
  5. Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii100-3 - PubMed
  6. DNA Cell Biol. 2012 Jun;31(6):983-7 - PubMed
  7. Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1222-6 - PubMed
  8. Clin Exp Rheumatol. 2005 Mar-Apr;23(2):159-64 - PubMed
  9. Mol Carcinog. 2009 Jul;48(7):626-32 - PubMed
  10. Int J Immunogenet. 2005 Jun;32(3):167-71 - PubMed
  11. J Immunol. 1988 Jul 15;141(2):662-6 - PubMed
  12. J Hepatol. 2010 Feb;52(2):252-7 - PubMed
  13. Eur J Immunol. 2000 Dec;30(12):3516-21 - PubMed
  14. Eur J Immunogenet. 2003 Dec;30(6):409-14 - PubMed
  15. J Cancer Res Clin Oncol. 2010 Jun;136(6):847-54 - PubMed
  16. Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1547-9 - PubMed
  17. Eur J Immunogenet. 1998 Dec;25(6):419-20 - PubMed
  18. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  19. Asian Pac J Cancer Prev. 2014;15(16):6961-7 - PubMed
  20. Annu Rev Biochem. 1994;63:1045-83 - PubMed
  21. Helicobacter. 2005 Jun;10(3):172-8 - PubMed
  22. Anticancer Res. 2005 Jul-Aug;25(4):2757-60 - PubMed
  23. Onco Targets Ther. 2015 Jul 17;8:1753-60 - PubMed
  24. DNA Cell Biol. 2010 Jul;29(7):363-8 - PubMed
  25. Anticancer Res. 2003 Jan-Feb;23(1A):149-53 - PubMed
  26. Mol Oncol. 2010 Jun;4(3):174-91 - PubMed
  27. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  28. Cell. 2008 May 30;133(5):775-87 - PubMed
  29. J Natl Cancer Inst. 1959 Apr;22(4):719-48 - PubMed
  30. Asian Pac J Cancer Prev. 2012;13(2):621-3 - PubMed
  31. Genet Test Mol Biomarkers. 2013 Jun;17(6):453-7 - PubMed
  32. DNA Cell Biol. 2012 Jul;31(7):1279-84 - PubMed
  33. Asian Pac J Cancer Prev. 2012;13(2):411-20 - PubMed
  34. J Gastroenterol Hepatol. 2008 Oct;23(10):1567-73 - PubMed
  35. Infect Genet Evol. 2014 Oct;27:375-81 - PubMed
  36. Hum Immunol. 2003 Oct;64(10):979-89 - PubMed

Publication Types